Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04516967
Recruitment Status : Recruiting
First Posted : August 18, 2020
Last Update Posted : February 15, 2021
Sponsor:
Information provided by (Responsible Party):
Dova Pharmaceuticals

Brief Summary:
A Phase 3b Study to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects with Immune Thrombocytopenia for ≥6 Months

Condition or disease Intervention/treatment Phase
Immune Thrombocytopenia Drug: Avatrombopag Drug: Placebo Phase 3

Detailed Description:
Subjects will be randomized in to blinded therapy of avatrombopag or placebo in a 3:1 ratio for a period of 12 weeks. Subjects who complete the 12 week treatment period and are eligible may continue to the open label extension phase which will last 2 years.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 72 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Supportive Care
Official Title: Randomized, Double-blind, Placebo-controlled Study With Open-label Extension Phase to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months
Estimated Study Start Date : February 2021
Estimated Primary Completion Date : May 22, 2023
Estimated Study Completion Date : May 15, 2025


Arm Intervention/treatment
Active Comparator: Experimental: Avatrombopag
Study is 3:1 randomization ratio (avatrombopag to placebo). Investigational product administered orally once daily for 12 weeks
Drug: Avatrombopag
Oral avatrombopag Tablet
Other Name: Doptelet

Placebo Comparator: Placebo Comparator:Placebo
Study is 3:1 randomization ratio (avatrombopag to placebo). Investigational product administered orally once daily for 12 weeks
Drug: Placebo
Placebo comparator tablet




Primary Outcome Measures :
  1. Durable platelet response [ Time Frame: Last 8 weeks of 12 week treatment regimen ]
    The proportion of subjects achieving at least 6 out of 8 weekly platelet counts ≥50×109/L during the last 8 weeks of the 12 week Treatment Period in the Core Phase, in the absence of rescue medication


Secondary Outcome Measures :
  1. Platelet Counts [ Time Frame: 12 weeks of treatment ]
    The percentage of weeks subjects have a platelet count ≥50×109/L during 12 weeks of treatment in the Core Phase, in the absence of rescue therapy.

  2. Platelet response [ Time Frame: Day 8 ]
    The proportion of subjects with a platelet count ≥50×109/L at day 8, in the absence of rescue therapy.

  3. Platelet percentage [ Time Frame: 12 weeks ]
    The percentage of weeks subjects have a platelet count between ≥50×109/L and ≤150×109/L, during 12 weeks of treatment in the Core Phase, in the absence of rescue therapy.

  4. Rescue medications [ Time Frame: 12 weeks ]
    The proportion of subjects who require rescue medications during 12 weeks of treatment in the Core Phase of the study.

  5. Bleeding Symptoms [ Time Frame: Throughout study ]
    Incidence and severity of bleeding symptoms associated with Immune thrombocytopenia ( ITP measured using the World Health Organization (WHO) Bleeding Scale.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Year to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female participants ≥1 and <18 years of age at Screening with a diagnosis of primary ITP for ≥6 months duration and has had an insufficient response to a previous treatment, in the opinion of the Investigator.
  • Participant has an average of 2 platelet counts <30×109/L with no single count >35×109/L in the screening period

Exclusion Criteria:

  • Participants must not have a known history of secondary ITP, any history of arterial or venous thrombosis, including partial or complete thrombosis, known inherited thrombocytopenia, a history of myelodysplastic syndrome (MDS) or known history of congenital heart abnormalities or arrhythmias.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04516967


Contacts
Layout table for location contacts
Contact: Dova Clincal 919-765-6671 clinical@dova.com

Locations
Layout table for location information
United States, Arizona
Dova Site Not yet recruiting
Phoenix, Arizona, United States, 85016
United States, California
Dova Site Not yet recruiting
Long Beach, California, United States, 90806
Dova Site Not yet recruiting
Orange, California, United States, 92868
Dova Site Not yet recruiting
Sacramento, California, United States, 95817
Dova Site Not yet recruiting
San Francisco, California, United States, 94158
United States, Colorado
Dova site Not yet recruiting
Aurora, Colorado, United States, 80045
United States, Florida
Dova Site Not yet recruiting
Gainesville, Florida, United States, 32610
United States, Georgia
Dova Site Not yet recruiting
Atlanta, Georgia, United States, 30322
United States, Illinois
Dova Site Recruiting
Peoria, Illinois, United States, 61615
United States, Massachusetts
Dova Site Not yet recruiting
Boston, Massachusetts, United States, 02115
United States, Minnesota
Dova Site Not yet recruiting
Minneapolis, Minnesota, United States, 55404
United States, Mississippi
Dova Site Not yet recruiting
Jackson, Mississippi, United States, 39216
United States, Nevada
Dova Site Not yet recruiting
Las Vegas, Nevada, United States, 89135
United States, New Jersey
Dova Site Not yet recruiting
Morristown, New Jersey, United States, 07960
United States, North Carolina
Dova Site Not yet recruiting
Charlotte, North Carolina, United States, 28203
Dova Site Not yet recruiting
Durham, North Carolina, United States, 27710
United States, Ohio
Dova Site Not yet recruiting
Columbus, Ohio, United States, 43205
United States, Pennsylvania
Dova Site Not yet recruiting
Philadelphia, Pennsylvania, United States, 19107
United States, Rhode Island
Dova Site Not yet recruiting
Providence, Rhode Island, United States, 02903
United States, Texas
Dova Site Not yet recruiting
Houston, Texas, United States, 77030
Sponsors and Collaborators
Dova Pharmaceuticals
Layout table for additonal information
Responsible Party: Dova Pharmaceuticals
ClinicalTrials.gov Identifier: NCT04516967    
Other Study ID Numbers: AVA-PED-301
First Posted: August 18, 2020    Key Record Dates
Last Update Posted: February 15, 2021
Last Verified: February 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Dova Pharmaceuticals:
ITP
Additional relevant MeSH terms:
Layout table for MeSH terms
Thrombocytopenia
Purpura, Thrombocytopenic, Idiopathic
Blood Platelet Disorders
Hematologic Diseases
Purpura, Thrombocytopenic
Purpura
Blood Coagulation Disorders
Thrombotic Microangiopathies
Hemorrhagic Disorders
Autoimmune Diseases
Immune System Diseases
Hemorrhage
Pathologic Processes
Skin Manifestations